Advertisement

Topics

A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

2016-07-04 23:11:18 | BioPortfolio

Published on BioPortfolio: 2016-07-04T23:11:18-0400

Clinical Trials [6148 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

This is a single center, open-label phase1b clinical trial. The study will evaluate the safety and immunogenicity of an experimental recombinant staphylococcus aureus vaccine with differen...

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

Before this study, there will be an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the prelimina...

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body. ...

An Evaluation of Three Dose Levels of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults

This study is a first-in-human (Phase 1) study using up to three doses of an investigational vaccine directed against Staphylococcus aureus (SA3Ag). This study is primarily designed to as...

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus

PubMed Articles [17994 Associated PubMed Articles listed on BioPortfolio]

Staphylococcus aureus Bacteraemia - an Interdisciplinary Challenge.

Staphylococcus aureus is the second-most-common pathogen among bloodstream infections. Due to a high hospital mortality rate (15 - 40%), frequent complications and recurrences the clinical managem...

Recombinant Staphylococcal Antigen-F (r-ScaF), a novel vaccine candidate against methicillin resistant Staphylococcus aureus infection: Potency and efficacy studies.

Staphylococcus aureus is a human commensal and pathogen, its clinical importance is exacerbated by the spread of multi-drug resistant strains. The potential future failure of antibiotic therapy necess...

Tracking Staphylococcus aureus in ICU using Whole-Genome Sequencing.

Staphylococcus aureus remains an important bacterial pathogen worldwide. This study utilized known staphylococcal epidemiology to track S. aureus between different ecological reservoirs in one ten-bed...

Clumping factor B is an important virulence factor during Staphylococcus aureus skin infection and a promising vaccine target.

Staphylococcus aureus expresses a number of cell wall-anchored proteins that mediate adhesion and invasion of host cells and tissues and promote immune evasion, consequently contributing to the virule...

A decade of antimicrobial resistance in Staphylococcus aureus: A single center experience.

The emergence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) resulted in the recommended use of clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) for suspected S. ...

Medical and Biotech [MESH] Definitions

A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS.

A 25-kDa peptidase produced by Staphylococcus simulans which cleaves a glycine-glcyine bond unique to an inter-peptide cross-bridge of the STAPHYLOCOCCUS AUREUS cell wall. EC 3.4.24.75.

Pneumonia caused by infections with bacteria of the genus STAPHYLOCOCCUS, usually with STAPHYLOCOCCUS AUREUS.

A protein present in the cell wall of most Staphylococcus aureus strains. The protein selectively binds to the Fc region of human normal and myeloma-derived IMMUNOGLOBULIN G. It elicits antibody activity and may cause hypersensitivity reactions due to histamine release; has also been used as cell surface antigen marker and in the clinical assessment of B lymphocyte function.

Protein exotoxins from Staphylococcus aureus, phage type II, which cause epidermal necrolysis. They are proteins with a molecular weight of 26,000 to 32,000. They cause a condition variously called scaled skin, Lyell or Ritter syndrome, epidermal exfoliative disease, toxic epidermal necrolysis, etc.

More From BioPortfolio on "A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial